

Subject: Update from Bayer Women's Healthcare Medical Affairs

Teaser: Learn about Publications, On-Demand CEs, and more

Learn About Publications, On-Demand CEs, and more

Visit online



Medical Affairs Quarterly Update

Women's Healthcare

Welcome to the Bayer Medical Affairs Women's Healthcare quarterly newsletter. Below you will find information on updated clinical recommendations, publications, accredited continuing education programs, and our upcoming congress activities related to Bayer's Women's Healthcare portfolio.

New Recommendations on Pain Management for IUD Insertion, Other In-Office Gynecologic Procedures

The American College of Obstetricians and Gynecologists (ACOG) has released guidance on pain management for in-office uterine and cervical procedures, emphasizing improved patient counseling and pain management options for commonly painful procedures like intrauterine device (IUD) insertion and endometrial biopsy.

ACOG highlights the importance of clinicians recognizing patient pain and advocating for greater patient autonomy in pain management choices. Recommendations include using local anesthetics for IUD insertion and encouraging individualized, culturally competent, trauma-informed discussions. The guidance also mentions the option of intravenous sedation or general anesthesia when available, aiming to enhance patient experiences, build trust, and ensure equitable access to necessary gynecologic care.

To read the complete guidance, click below to learn more.

Learn More

Recent Publications

Trigg A, et al.	Psychometric evaluation of the HFDD, PROMIS SD SF 8b, and MENQOL questionnaire in women experiencing vasomotor symptoms associated with menopause	<i>J Patient Rep Outcomes</i> (May 2025)
Eggebrecht L, et al.	Real-world use of antispasmodic drugs during IUD insertion - insights from the large observational study EURAS-LCS12	<i>Eur J Contracept Reprod Health Care</i> (Apr 2025)
Eggebrecht L, et al.	Population characteristics of intrauterine device users in real-world clinical practice across Europe – insights from the EURAS-LCS12 study.	<i>Contracept Reprod Med</i> (Mar 2025)
Mackenzie A, et al.	Consensus recommendations for measuring the impact of contraception on the menstrual cycle in contraceptive clinical trials	<i>Contraception</i> (Jan 2025)

For additional publications, please visit [medicalaffairs.bayer.com](#)

Accredited Continuing Education

This information is being offered for your educational purposes only. Bayer is not responsible for, nor has any control over, the content presented by any independent website or entity.

Turning Down the Heat: Exploring Newly Approved and Emerging Nonhormonal Therapies for Menopause-Associated VMS

Upon completion of this activity, participants should be able to:

- Recognize the rationale for novel nonhormonal therapies in the treatment of VMS associated with menopause
- Review the clinical profiles of approved and emerging novel nonhormonal treatments of VMS associated with menopause
- Outline patient-centered, evidence-based strategies to optimize the treatment of common menopausal symptoms

0.5-hour presentation webcast. Available until September 29, 2025.

CLICK TO ACCESS

Preparing for the Spectrum of Menopause Symptoms: Evolving Strategies and Expert Insights

Upon completion of this activity, participants should be able to:

- Have increased knowledge regarding the:
 - Strategies to support early menopause interventions in the primary care setting
 - Broad impact of menopause on patient quality of life
 - Understanding of the role of emerging nonhormonal treatments in managing the spectrum of menopause-related symptoms

1-hour on-demand video. Available until October 11, 2025.

CLICK TO ACCESS

VMS in Menopause

Upon completion of this activity, participants should be able to:

- Describe the burden and undertreatment of menopause-associated VMS and the impact of these symptoms on patients' quality of life
- Incorporate clinical safety and efficacy data for new and emerging therapies into treatment regimens for VMS
- Develop patient-specific therapeutic regimens for patients with VMS, including hormonal and nonhormonal therapies as appropriate

1-hour on-demand video. Available until December 15, 2025.

CLICK TO ACCESS

Evaluating the Effectiveness and Value of Novel Nonhormonal Treatments in the Management of Menopause-Related Vasomotor Symptoms

Upon completion of this activity, participants should be able to:

- Explain the health burden associated with VMS in menopause and the risk/benefit profile of hormonal therapy
- Examine the efficacy and safety data for novel nonhormonal therapies in the treatment of bothersome menopause symptoms, including VMS and sleep disturbances
- Explore the health care resource utilization and economic burden associated with VMS and the need for a personalized treatment approach to improve menopause-related quality of life

1.5-hour on-demand video. Available until April 10, 2026.

CLICK TO ACCESS

From Hot Flashes to Sleepless Nights: Evolving Strategies for Navigating the Full Range of Menopause Symptoms

Upon completion of this activity, participants should be able to:

- Have increased knowledge regarding the latest advances related to managing the spectrum of menopause symptoms
- Have greater competence related to assessing severity of symptoms to identify patients with menopause-associated symptoms
- Demonstrate greater confidence in their ability to evaluate the latest advances related to emerging nonhormonal treatments in managing the spectrum of menopause-related symptoms

1-hour on-demand video. Available until May 28, 2026.

CLICK TO ACCESS

Do It Better: Raising the Bar in Menopause Care With Individualized Approaches to VMS Treatment

Upon completion of this activity, participants should:

- Identify the key aspects of pathophysiology, clinical presentation, and the burden of VMS in menopause
- Evaluate the latest evidence on both hormonal and nonhormonal therapies for VMS to better inform patients about the benefits and risks
- Tailor counseling strategies to individual patient profiles, enabling personalized discussions on the management and treatment options for VMS during menopause

1.5-hour on-demand video. Available until June 9, 2026.

CLICK TO ACCESS

Congress Calendar

See below for a list of congresses where you can find Bayer Women's Healthcare Medical Affairs.


October 2025	The National Association of Nurse Practitioners in Women's Health (NPWH) October 1–3, 2025, Las Vegas, NV NPWH
October 2025	The Menopause Society (TMS) October 21–25, 2025, Orlando, FL TMS

Other Research and Educational Resources

Bayer's US Medical Affairs website is an educational resource for US healthcare providers to access scientific and clinical information.

Available at [medicalaffairs.bayer.com](#).

If you have any questions, visit <https://askmed.bayer.com>.



©2025 Bayer. Bayer and the Bayer Cross are registered trademarks of Bayer. All rights reserved.

Bayer Corporation, 100 Bayer Blvd., Whippany, NJ 07981

MA-PFM-WHC-US-0084-2

Please note that this email address is not monitored for replies.

If you would like to contact us, visit our [Contact us](#) section online.

[Terms of use](#) | [Privacy policy](#) | [Unsubscribe](#)

This message is brought to you by Bayer US Medical Affairs.